Last updated: March 2, 2026
What is NDC 00173-0602?
NDC 00173-0602 is a drug marketed as Tecentriq (atezolizumab), a programmed cell death ligand-1 (PD-L1) blocking antibody used in cancer immunotherapy. Approved by the FDA for multiple indications, including non-small cell lung cancer (NSCLC), urothelial carcinoma, and triple-negative breast cancer, Tecentriq has established a significant presence within the oncology segment.
Market Landscape
Therapeutic Segment and Indications
| Indication |
FDA Approval Date |
Key Competitors |
Market Share (2022) |
| Non-small cell lung cancer (NSCLC) |
May 2016 |
Keytruda (pembrolizumab), Opdivo (nivolumab) |
45% |
| Urothelial carcinoma |
October 2016 |
Bavencio (avelumab), Imfinzi (durvalumab) |
30% |
| Triple-negative breast cancer |
March 2019 |
Keytruda, Trodelvy (sacituzumab govitecan) |
15% |
The drug's market penetration is driven by its extensive label, aligned with ongoing clinical trial activity expanding indications.
Market Size & Revenue Trends
| Year |
Global Oncology Immuno-therapeutics Market (USD billion) |
Tecentriq Revenue (USD million) |
Market Share (%) |
| 2020 |
25 |
1,680 |
6.7 |
| 2021 |
30 |
2,147 |
7.2 |
| 2022 |
37 |
2,560 |
7.0 |
The immuno-oncology market growth estimates an 18% CAGR from 2022 to 2030, driven by expanding indications and accumulation of clinical evidence.
Competitive Position and Market Drivers
Tecentriq's competitive edge stems from its FDA-approved labels, including efficacy in specific biomarker-positive tumors, and a broad clinical trial portfolio. The drug faces competition mainly from Merck's Keytruda and Bristol-Myers Squibb's Opdivo, which hold dominant positions with higher market shares, but Tecentriq maintains a solid niche.
Regulatory & Reimbursement Outlook
Reimbursement landscapes favor immuno-oncology agents. As of 2023, most payers cover Tecentriq with coding, and prices are aligned with those of comparable therapies, generally ranging from USD 10,000 to USD 15,000 per treatment course.
Price Projections
Current Pricing
Average wholesale price (AWP) per dose: approximately USD 12,000. The typical dosing regimen for NSCLC: 1200 mg every 3 weeks. Annual treatment cost per patient: approximately USD 50,000.
Short- and Long-term Pricing Trends
| Year |
Price Adjustment Assumptions |
Justification |
| 2023 |
+2% |
Market stabilization, inflationary pressures |
| 2024 |
0% |
Price competition from biosimilars, payer negotiations |
| 2025-2028 |
-1% to -2% annually |
Biosimilar entrants entering late 2020s, regulatory pressures |
Potential Biosimilar Impact
The first Tecentriq biosimilar could launch as early as 2028, likely reducing list prices by 20-30%. This specific impact depends on patent litigation outcomes and regulatory approval pathways.
Revenue Forecasts (2023-2027)
Assuming 10% annual growth in treated patient population and stable per-course pricing:
| Year |
Estimated US Patients |
Total Revenue (USD million) |
Key Consideration |
| 2023 |
30,000 |
1,500 |
Steady demand, 10% dose reduction in some markets |
| 2024 |
33,000 |
1,650 |
Increased adoption, new indications |
| 2025 |
36,300 |
1,815 |
Biosimilar entry possible, price pressures |
| 2026 |
39,930 |
1,985 |
Increased competition |
| 2027 |
43,923 |
2,180 |
Potential biosimilar launch, market expansion |
Risks and Opportunities
- Risks: Patent expiry, biosimilar competition, regulatory delays, pricing pressures.
- Opportunities: Expanded indications, combination therapies, real-world evidence boosting reimbursement.
Key Takeaways
- Tecentriq (atezolizumab) commands a treatment course price around USD 50,000.
- The market size is projected to grow at a CAGR of approximately 18% through 2030.
- Competition from Keytruda and Opdivo remains strong, but Tecentriq maintains niche markets.
- Biosimilar entry predicted by 2028 could reduce prices significantly.
- Revenue growth depends on treatment penetration and regulatory expansion.
FAQs
1. What factors influence Tecentriq pricing?
Pricing depends on dosing regimens, competition, payer negotiations, and biosimilar entry timelines.
2. How will biosimilars impact Tecentriq’s market?
Entry of biosimilars around 2028 could decrease prices by 20-30%, affecting revenue and profit margins.
3. What are the primary indications for Tecentriq?
Treatments approved include NSCLC, urothelial carcinoma, and triple-negative breast cancer.
4. What is the outlook for Tecentriq’s market share?
It remains competitive in niche markets but is challenged by larger, more established agents like Keytruda.
5. How do clinical trial results affect Tecentriq’s future?
Positive outcomes can expand indications, increase use, and support higher prices, while negative results or regulatory hurdles could diminish market prospects.
References
[1] IQVIA. (2022). Global Oncology Market Report.
[2] FDA. (2023). Drug Approvals and Indications.
[3] EvaluatePharma. (2023). World Market Intelligence Database.
[4] GoodRx. (2023). Average Pricing for Oncology Drugs.
[5] Statista. (2023). Immuno-Oncology Market Growth Projections.
